Rare Opening In Tough Times: New Biotechs Rekindle CNS Development In China

But Regulatory Barriers Remain

 
• By Brian Yang
  
nerve cells, concept for neurodegenerative and neurological disease
Chinese biotechs flock to CNS development but funding, regulatory worries remain • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from China

More from Focus On Asia